immunotherapy

Jaffee looks to the future of checkpoint immunotherapy for cancer treatment

Jaffee looks to the future of checkpoint immunotherapy for cancer treatment

Posted by  | Issues & Perspectives, precision medicine, Prevention/Screening, treatment

Combinations strategies involving checkpoint immunotherapies were approved as first-line options in two cancer types and showed promise in clinical trials for several hard-to-treat cancers. Important advances were also made with respect to immune-related biomarkers, cellular immunotherapies, and personalized vaccines. Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, is focusing her research(...)

Benefits of Immunotherapy in Metastatic Non-Small Cell Lung Cancer

Posted by  | Issues & Perspectives, Research, Survivorship

Julie Brahmer, M.D., is an active clinical leader in the treatment of lung cancer and mesothelioma. As the director of the Thoracic Oncology Program and professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, her research and clinical practice focuses on the development of new therapies for the treatment and prevention(...)

Immunotherapy for Lung Cancer

Immunotherapy for Lung Cancer

Posted by  | precision medicine, treatment

It’s lung cancer awareness month. Hear lung cancer expert Julie Brahmer and cancer genetics expert Victor Velculescu explain how immunotherapy is becoming a game changer for certain patients. Learn about the latest advances from our Bloomberg~Kimmel Institute for Cancer Immunotherapy and how we are helping patients with lung cancer live better and longer. Watch the(...)

Pancreatic Cancer Awareness Month

Pancreatic Cancer Awareness Month

Posted by  | Issues & Perspectives, treatment

It’s Pancreatic Cancer Awareness Month, so we wanted to gather our best Kimmel Cancer Center resources for you. Learn more about cancer vaccines and other ways our experts are working to get the immune system to fight pancreatic cancer. Watch leading pancreatic cancer and immunology expert Elizabeth Jaffee, M.D., talk about new work from our(...)

‘Individualized’ Immune Cell Engineering Therapy for Cancer Clears First FDA Hurdle

‘Individualized’ Immune Cell Engineering Therapy for Cancer Clears First FDA Hurdle

Posted by  | precision medicine

*Update Aug. 30, 2017 - The FDA has approved the CAR-T therapy tisagenlecleucel for certain leukemia patients. News of an FDA advisory committee that has reviewed one pharmaceutical company's approach to engineering a cancer patient's own T-cells, the so-called soldiers of the immune system, and injecting them back into patients with astounding success has prompted questions(...)

Historic cancer drug approval has roots at Johns Hopkins and its Bloomberg~Kimmel Institute laboratories and clinics

Historic cancer drug approval has roots at Johns Hopkins and its Bloomberg~Kimmel Institute laboratories and clinics

Posted by  | Issues & Perspectives

Breaking news today as, for the first time, a drug has been FDA-approved for cancer based on disease genetics rather than type. Developed from 30 years of basic research at Johns Hopkins and its Bloomberg~Kimmel Institute, pembroluzimab now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in(...)

Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children

Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children

Posted by  | Childhood Cancer, Research

Johns Hopkins undergraduate student Sabrina Wang won first place in a competition among 125 students for her research on a lethal type of pediatric brain tumor called atypical teratoid/rhabdoid tumors (AT/RT), the most common brain tumor type in infants. The award was presented at the AACR 2017 annual meeting in Washington, D.C., on April 2.(...)